Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Agile Therapeutics Inc. AGRX

Alternate Symbol(s):  AGXRW

Agile Therapeutics Inc is a women's healthcare company to fulfill the unmet health needs of women. Its product candidates are designed to provide women with contraceptive options. The firm's initial product, Twirla, (levonorgestrel and ethinyl estradiol) transdermal system is a non-daily prescription contraceptive. Twirla is based on proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin.


Recent & Breaking News (NDAQ:AGRX)

Agile Therapeutics Reports Third Quarter 2019 Financial Results

GlobeNewswire October 28, 2019

Agile Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire September 6, 2019

Agile Therapeutics Announces Full Exercise of Over-Allotment Option by Underwriters

GlobeNewswire August 8, 2019

Agile Therapeutics Announces Pricing of $12 Million Underwritten Public Offering of Common Stock

GlobeNewswire August 2, 2019

Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

GlobeNewswire August 1, 2019

Agile Therapeutics Reports Second Quarter 2019 Financial Results

GlobeNewswire August 1, 2019

Agile Therapeutics Appoints Chief Financial Officer

GlobeNewswire July 18, 2019

Agile Therapeutics Announces FDA Advisory Committee Meeting for its Investigational Transdermal Low-Dose Contraceptive Patch, Twirla® (AG200-15)

GlobeNewswire June 24, 2019

Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®

GlobeNewswire May 22, 2019

Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch, Twirla®

GlobeNewswire May 17, 2019

Agile Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 9, 2019

Agile Therapeutics to Present Combined Safety Data from Three Phase 3 Studies at the 2019 ACOG Annual Meeting

GlobeNewswire May 3, 2019

Agile Therapeutics Reports First Quarter 2019 Financial Results

GlobeNewswire May 2, 2019

Agile Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference in London, UK

GlobeNewswire March 28, 2019

Agile Therapeutics to Present In Vivo Adhesion Data from Two Phase 1 Studies at the 2nd Annual Formulation & Drug Delivery USA Congress

GlobeNewswire March 15, 2019

Agile Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

GlobeNewswire March 12, 2019

Agile Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire March 11, 2019

Agile Therapeutics Announces $7.8 Million Private Placement

GlobeNewswire March 4, 2019

35 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  February 11, 2019

26 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  February 11, 2019